Synthetic pan-ERR agonist

SLU-PP-332

ERRα/β/γ

SLU-PP-332 is not a peptide but a small synthetic molecule that activates all three estrogen-related receptors. It is used as an experimental tool to study exercise-like gene programmes and energy expenditure in cells and mice.

1Overview
2× / dayReference frequency
DataCell and animal studies
Research status

Preclinical only; no human dosing

Velora SLU-PP-332 vial
SLU-PP-3325 MG
01 · Overview

What is SLU-PP-332?

SLU-PP-332 is not a peptide but a small synthetic molecule that activates all three estrogen-related receptors. It is used as an experimental tool to study exercise-like gene programmes and energy expenditure in cells and mice.

Research route, formulation and population determine what a result actually means.

01

ERRα/β/γ

Activates ERRα/β/γ and changes expression of mitochondrial and oxidative genes.

02 · Research

What do the studies show?

Cell and animal studies. Educational information. Not diagnosis, treatment or use advice.

Mice
Preclinical

Exercise capacity

Treatment increased oxidative muscle fibres and running endurance in mice; this does not establish a human effect.

03 · DATA

Peptide and product specifications

Checked identity data for this research compound or blend.

SLU-PP-332Peptide and product specifications
Product type
Synthetic small molecule; not a peptide
Molecular formula
C₁₈H₁₄N₂O₂
Molecular weight
290.3 g/mol
CAS number
303760-60-3
Purity
Batch-specific - confirm identity and purity with the Velora COA
Reference diluent
Formulation- and batch-specific; there is no universal diluent for every research compound
Unreconstituted-material storage
Follow the accompanying COA, product label and validated stability data

These are compound references, not a batch certificate. Purity and identity of a specific Velora batch must be confirmed by its accompanying COA and laboratory report.

NIH PubChem identity record ↗
04 · Calculator

Reconstitution and U-100 conversion

This module only converts concentration and volume. Inputs are not recommendations or individual dosing advice.

Calculator

Twice daily in mouse models

1
2
3
4
Draw to
0 units
0.00 mL
SLU-PP-332 vial
SLU-PP-332
5 MG
Concentration-
Per unit-
Complete amounts-
Calculated duration-
LAB · RECONSTITUTION

How to reconstitute SLU-PP-332 for laboratory research

A visual workflow for controlled laboratory reconstitution. Always follow the product label, COA and a validated protocol.

Five visual laboratory reconstitution steps: clean, measure diluent, add slowly, swirl gently and store according to protocol.
1

Clean

Disinfect the rubber closures of both vials and allow them to dry.

2

Measure diluent

Withdraw only the diluent validated for the specific compound.

3

Add slowly

Let the liquid run slowly down the inside wall of the vial.

4

Swirl gently

Do not shake; rotate gently until the material has dissolved.

5

Store per protocol

Follow the product label, COA and validated stability data.

Important checks before and after reconstitution

Check the product

First confirm that the product is a lyophilised vial. Prefilled pens and ready-to-use solutions do not require reconstitution. Check the label, COA and specified diluent.

Use clean, sterile technique

Wash your hands, clean the work surface and use new sterile equipment for every procedure. Clean both rubber closures with separate alcohol swabs and let them dry completely.

Concentration, not total amount

The volume of liquid added changes the concentration in mg per mL, but not the total amount of research compound in the vial. Use the calculator to check this in advance.

Inspect and label

Check for unexpected discoloration, cloudiness or visible particles. Record the compound, concentration and reconstitution date. Storage time and temperature are product-specific; a fixed 28-day rule does not apply to every compound.

General reconstitution volumes listed by the source

General examples, not a product-specific protocol. The chosen volume determines concentration; always check the label, COA and calculator.

Vial strengthCommonly listed volume
2 mg1–2 mL
5 mg2–3 mL
6 mg2–3 mL
10 mg2–4 mL
15 mg3–5 mL
20 mg4–8 mL

Practical background source: Free Medical Journals - Complete Step-by-Step Guide to Peptide Reconstitution, accessed July 2026. This is a secondary educational source; the product label, COA and validated stability data remain authoritative.

05 · Safety and limitations

Safety and limitations

Research route, formulation and population determine what a result actually means.

What is known

  • Visible research claims use primary or official sources.
  • The calculator is arithmetic and does not turn a study amount into medical advice.
  • A registered medicine and a research vial are not automatically equivalent.

What remains uncertain

  • Many products lack long-term safety data and independent replication.
  • Animal and cell findings do not predict a safe human dose.
  • Stability depends on formulation, pH, sterility, light, temperature and packaging.
Status: Preclinical only; no human dosing. Educational information. Not diagnosis, treatment or use advice.
06 · FAQ

Frequently asked questions

SLU-PP-332 is not a peptide but a small synthetic molecule that activates all three estrogen-related receptors. It is used as an experimental tool to study exercise-like gene programmes and energy expenditure in cells and mice.
Treatment increased oxidative muscle fibres and running endurance in mice; this does not establish a human effect. No published human safety, pharmacokinetic or efficacy trials are available.
No. It performs arithmetic conversions only. Medical decisions belong with a licensed healthcare professional.
The curve follows the agreed storage model and is not a laboratory result.
2–8 °C. Protect from light and repeated freeze-thaw cycles.
07 · Sources

Primary research sources

Educational information. Not diagnosis, treatment or use advice.

Synthetic ERRα/β/γ Agonist Induces an Acute Aerobic Exercise Response ACS Chemical Biology, 2023. Link
A Synthetic ERR Agonist Alleviates Metabolic Syndrome Journal of Pharmacology and Experimental Therapeutics, 2024. Link